Consistent with AP-1 potentiating GLI activity, knockdown of JUN, JUNB, JUND, and FOSL2 levels or treatment with AP-1 inhibitors (T5224 and SR11302) decreases GLI1 expression and viability in BCC cells ([93] and Table 2). The gene discussed is FOSL2; the disease is skin basal cell carcinoma.